Pharmacer Holdings PHRRF and the Terasaki Biomedical Innovation Institute evaluated a new microneedle patch for the former DMT delivery and found positive results in the study.
In this study, we aimed to develop a prototype of PharmaPatch suitable for transdermal delivery of DMT to overcome the obstacles associated with oral and IV administration routes.
The study resulted in a complete characterization of DMT bound to the backbone of the microneedle patch, establishment and demonstration of DMT’s loading capacity, and evaluation of the release kinetics of the psychedelic binding material.
DMT microneedles were reportedly “successfully fabricated, optimized and characterized” and demonstrated “acceptable performance” in male and female rats.
The authors conclude that the smooth uptake of DMT into microneedles and the demonstration of complete ex vivo skin model release over several days suggest the potential for larger doses, modified release profiles, and microdosing. said to suggest
enter the clinic
PharmaPatch’s delivery technology is based on a novel biocompatible and biodegradable gelatin-methacryloyl (GelMA) material that safely delivers water-soluble and insoluble drugs with specified release profiles by penetrating the outer layer of the skin. reportedly can be delivered in an efficient and efficient manner.
PharmaTher has completed a research study demonstrating that its microneedle patch can deliver other hallucinogens, including psilocybin, MDMA and LSD, and the prototype PharmaPatch has achieved is next capable of an IND to enter clinical studies. I believe that I will be accepted to complete the studies I will do.
In addition to working with research partner PharmaDrug, the company will invest $227,700 (C$300,000) in its subsidiary Cyrillo Therapeutics to acquire a 49% stake.
Sairiyo is developing novel uses and delivery forms of DMT and other undisclosed tryptamines as potential treatments for ocular and neuropsychiatric disorders.
In connection with this investment, PharmaDrug and Pharmacer entered into a unanimous shareholder agreement with respect to Sairyo’s holdings regarding the right to appoint management and the composition of the board of directors, as well as the rights of shareholders to subscribe to new share issuances on a pro-rata basis. It is scheduled to be concluded.
Want to stay up to date on the latest in the cannabis business world? Join Benzinga’s Cannabis Capital Conference and stay ahead!
The 17th Annual CCC in Chicago on September 27th and 28th is the place to make the deal happen. Buy your tickets now and join us before prices go up.
Photo: Benzinga, DyrElena photo edited with Shutterstock and Wikimedia Commons.
